CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Analysts have also weighed in on stock throughout the month. Recent analyst calls on the stock include: Needham analyst Gil ...

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...

Mr. Mahatme brings decades of experience in strategic finance, capital formation, and operational leadership to support ...

ARK Innovation ETF (BATS: ARKK) is pushing to fresh 52-week highs Thursday, buoyed by strong performances from its key ...

With half a million people having already received multi-cancer early detection (MCED) screening, patients are and will continue to be asking about these blood tests during their visits, physicians ...

We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...

Technology can be harnessed to design novel and enhanced molecules that address challenges in biotechnology or medicine. Australian researchers, including those at the Charles Perkins Centre at the ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

Investors have become quite familiar with the Magnificent Seven, the group of tech giants that reshaped markets with their ...

The drug, which Repare recently sidelined, has shown promising activity in a patient with ALT-positive melanoma that researchers want to study in others.